In isolated guinea-pig trachea, ipratropium bromide inhibited electrically evoked cholinergic contraction with an IC50 of 0.58 nM. At 10 nM, the washout half-recovery time was 81.2±3.7 min, compared with 26.4±0.5 min for glycopyrrolate (mean±s.e.mean). [1]
With carbachol-induced contraction in a separate guinea-pig tracheal study, ipratropium showed a pIC50 of 8.6±0.02 and a washout half-recovery time of 0.5±0.1 h (mean±s.e.m.). At 10 nM it did not inhibit neurokinin A-induced tone. The relative duration versus glycopyrrolate differed from the EFS experiment, so duration should remain tied to the assay conditions. [2,1]
In isolated human bronchial rings precontracted with carbachol, ipratropium produced a pIC50 of 9.5±0.04. After washout of 10 nM ipratropium, the response reached 50% recovery at 3.0±0.2 h and 110±10% recovery at 6 h (mean±s.e.m.). It did not inhibit neurokinin A-induced tone at 10 nM. These are tissue-bath findings from surgical specimens. [2]
Muscarinic receptor binding in rat tissue membranes
Biochemical assay · Wistar rat cerebral cortex (M1-enriched), heart (M2-enriched) and salivary-gland (M3-enriched) membranes. [1]
Ipratropium bromide competed for radioligand binding at all three tissue-defined receptor populations. These are native-tissue affinity measurements, not cloned human receptor subtype measurements.
Literature-Reported Treatment Conditions
- Exposure duration
- 2.5–3 h incubation at 30°C
- Method
- Competitive radioligand binding; native tissue membranes.
- Vehicle
- 25 mM Tris buffer, pH 7.4; ipratropium stock solvent not specified in the read Drugs section.
- Co-treatment
- None; glycopyrrolate was a separate comparator.
- Reported limits
- Ipratropium competitor concentration range and hydration/stereochemical composition are not specified in the read assay text; no range inferred from the glycopyrrolate-only Figure 5.
Methods and source locations
Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium
Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.
Table 1 (image); Methods: Radioligand binding studies; Drugs and chemicals; Results: Selectivity of glycopyrrolate for M1–M3 receptors
Competition with [3H]-telenzepine in rat cerebral cortex: 0.4 nM radioligand; 30°C, 2.5–3 h; 1 μM atropine defined nonspecific binding. Mean±s.e.mean of 4–6 independent experiments performed in duplicate on separate membrane preparations. — Table 1, ipratropium bromide row, cerebral cortex; Methods: Binding assays
Competition with [3H]-NMS in rat heart: 0.3 nM radioligand; same binding assay controls and replication semantics as Table 1. — Table 1, ipratropium bromide row, heart; Methods: Binding assays
Competition with [3H]-NMS in rat salivary glands: 0.3 nM radioligand; same binding assay controls and replication semantics as Table 1. — Table 1, ipratropium bromide row, salivary glands; Methods: Binding assays
Inhibition and washout of nerve-evoked guinea-pig tracheal contraction
Cell-based study · Epithelium-denuded isolated tracheal strips from male Dunkin–Hartley guinea-pigs (250–500 g). [1]
Ipratropium bromide inhibited electrically evoked cholinergic contraction. At 10 nM, recovery after washout was slower than for glycopyrrolate in this EFS assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 nM for onset/washout; concentration–response assay reported separately.
- Exposure duration
- Until maximal inhibition, followed by washout and repeat EFS to 50% recovery; fixed exposure duration not reported.
- Method
- Isometric tension in organ baths at 37°C; four stable EFS responses before antagonist addition.
- Vehicle
- Krebs–Henseleit solution; ipratropium stock solvent not specified in read Drugs section.
- Co-treatment
- No therapeutic combination; indomethacin 10 μM throughout, propranolol 1 μM before experiment, capsaicin 10 μM pretreatment followed by washout. Glycopyrrolate in separate preparations.
- Reported limits
- Exact concentration series was not tabulated; no points digitized. Reported n is animal-based in captions.
Methods and source locations
Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium
Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.
Figures 1–2 and captions; Results: Functional characteristics in guinea-pig trachea; Methods: Guinea-pig trachea and Statistical analysis
50% inhibition of EFS-induced cholinergic contraction: EFS at 4 Hz, 40 V, 0.5 ms, 15 s every 4 min; fitted concentration–inhibition curve. Exact IC50 from Results text, not read from graph. — Results: Potency of antagonists in inhibiting contractile responses to EFS; Figure 1
Time to 50% inhibition after antagonist addition: 10 nM ipratropium; mean±s.e.mean. Values interpolated by authors from time-effect curves. — Results: Time course for antagonists, guinea-pig; Figure 2A; Statistical analysis
Time to 50% recovery of cholinergic contraction after washout: 10 nM ipratropium; mean±s.e.mean; glycopyrrolate 10 nM comparator: 26.4±0.5 min, n=3. Appropriate antagonist-free time controls were included. — Results: Time course for antagonists, guinea-pig; Figure 2B; Methods: Protocol
Reversal and recovery of carbachol-induced guinea-pig tracheal contraction
Cell-based study · Isolated tracheal preparations from male albino Dunkin–Hartley guinea-pigs, 450–550 g. [2,1]
Ipratropium reversed carbachol-induced contraction, followed by recovery after washout. It did not relax neurokinin A-induced tone at the tested concentration.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 nM for washout and neurokinin A controls; cumulative concentration–response for pIC50.
- Exposure duration
- Antagonist maintained until complete and sustained relaxation; carbachol challenges for 4.5 h after washout.
- Method
- Isometric tension at 37°C; 0.3 μM carbachol precontraction; isoprenaline 0.3 μM as maximal inhibitory reference; matched vehicle-treated preparations.
- Vehicle
- 10 mM stock in 100% DMSO, diluted with saline; organ-bath Krebs–Henseleit solution. A 1% DMSO-in-saline control was inactive.
- Co-treatment
- None; glycopyrrolate and tiotropium tested separately.
- Reported limits
- Exact ipratropium contact time and final in-vitro DMSO percentage are not specified in the read methods. Table n is observations, not necessarily independent donors/animals.
Methods and source locations
Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium
Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.
Table 1; Figure 2 and caption; Methods: tissue preparation, antagonist potency/offset; Chemicals; corresponding Results; Results: guinea-pig EFS time course; Figure 2B
50% reversal of carbachol-induced tonic contraction: −log10 molar IC50; mean±s.e.m., at least four observations. Cumulative antagonist curve on preparations precontracted with 0.3 μM carbachol. — Table 1, ipratropium row, guinea-pig trachea; Figure 2A
Time to 50% recovery of carbachol response after antagonist washout: 10 nM ipratropium; mean±s.e.m., at least four observations; repeated carbachol challenges at 45 min intervals. — Table 1 and footnotes; Figure 2B
Recovery of initial response to carbachol after washout: Mean±s.e.m., at least four observations; Figure 2 caption gives four to six observations. Recovery values can exceed 100% and are not percent inhibition. — Table 1, ipratropium row; Figure 2B
Relaxation of neurokinin A-induced smooth-muscle tone: Neurokinin A 1 μM; Results explicitly reports data not shown. This negative control supports stimulus-dependent action. — Results: Duration of antimuscarinic activity in the guinea-pig isolated trachea; neurokinin A control paragraph
Reversal and recovery of carbachol-induced human bronchial contraction
Cell-based study · Epithelium-denuded isolated human bronchial rings (1–5 mm internal diameter), macroscopically normal tissue from six lung-cancer surgery patients (four males), ages 48–66 years. [2]
Ipratropium reversed carbachol-induced contraction, followed by recovery after washout. It did not relax neurokinin A-induced tone at the tested concentration.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 nM for washout and neurokinin A controls; cumulative concentration–response for pIC50.
- Exposure duration
- Antagonist maintained until complete and sustained relaxation; carbachol challenges for 6.0 h after washout.
- Method
- Isometric tension at 37°C; 1 μM carbachol precontraction; isoprenaline 0.3 μM as maximal inhibitory reference; matched vehicle-treated preparations.
- Vehicle
- 10 mM stock in 100% DMSO, diluted with saline; organ-bath Krebs–Henseleit solution. A 1% DMSO-in-saline control was inactive.
- Co-treatment
- None; glycopyrrolate and tiotropium tested separately.
- Reported limits
- Exact ipratropium contact time and final in-vitro DMSO percentage are not specified in the read methods. Table n is observations, not necessarily independent donors/animals.
Methods and source locations
Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium
Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.
Table 1; Figure 3 and caption; Methods: tissue preparation, antagonist potency/offset; Chemicals; corresponding Results
50% reversal of carbachol-induced tonic contraction: −log10 molar IC50; mean±s.e.m., at least four observations. Cumulative antagonist curve on preparations precontracted with 1 μM carbachol. — Table 1, ipratropium row, human bronchus; Figure 3A
Time to 50% recovery of carbachol response after antagonist washout: 10 nM ipratropium; mean±s.e.m., at least four observations; repeated carbachol challenges at 60 min intervals. — Table 1 and footnotes; Figure 3B
Recovery of initial response to carbachol after washout: Mean±s.e.m., at least four observations; Figure 3 caption gives four to six observations. Recovery values can exceed 100% and are not percent inhibition. — Table 1, ipratropium row; Figure 3B
Relaxation of neurokinin A-induced smooth-muscle tone: Neurokinin A 1 μM; Results explicitly reports data not shown. This negative control supports stimulus-dependent action. — Results: Duration of antimuscarinic activity in the human isolated bronchus; neurokinin A control paragraph